The currently most potent small molecule Hsp90/Cdc37 interface inhibitor, compound (18 h) (Kd = 0.5 μM) was more efficacious in reducing the growth of HCT116 cell-derived colorectal cancer xenografts than its predecessor, DDO-5936. Here, HSP90AB1 is linked to colorectal cancer.